Építés alatt – nem éles oldal
Belépés
VisszavonvaNo phase

Predictive Value of PET/CT for Efficacy of Neoadjuvant Immunotherapy in Non-small Cell Lung Cancer

Megadott ok: Unable to support implementation.

Key facts

Where
Shanghai, KínaSee the 2 sites

Where in Kína

  • Shanghai East HospitalShanghai, KínaNo longer taking part
  • Shanghai Pulmonary HospitalShanghai, KínaNo longer taking part

Trial details

Who runs it
Shanghai Pulmonary Hospital, Shanghai, China
Trial code
NCT06895941
Record updated
2025. április 8.
Original description
The aim of this study was to investigate the enhancement of FAPI PET/CT metabolic parameters in predicting the efficacy performance of neoadjuvant immunotherapy using the pCR status of surgically resected specimens of lung cancer as the gold standard.Read full original descriptionShow less

The aim of this study was to investigate the enhancement of FAPI PET/CT metabolic parameters in predicting the efficacy performance of neoadjuvant immunotherapy using the pCR status of surgically resected specimens of lung cancer as the gold standard.

Inclusion: -.

Exclusion: -.

ClinicalTrials.gov NCT06895941